

**TRADEMARK ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
MedImmune, Inc.		12/14/2006	CORPORATION: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	ZLB Behring AG		
<b>Street Address:</b>	Wankdorfstrasse 10		
<b>City:</b>	Bern 22		
<b>State/Country:</b>	SWITZERLAND		
<b>Postal Code:</b>	CH-3000		
<b>Entity Type:</b>	CORPORATION: SWITZERLAND		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	1742103	CYTOGAM	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	(215)864-9260		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
<b>Phone:</b>	215.864.8148		
<b>Email:</b>	levanosf@ballardspahr.com		
<b>Correspondent Name:</b>	Paul Lantieri III		
<b>Address Line 1:</b>	1735 Market Street, 51st Floor		
<b>Address Line 4:</b>	Philadelphia, PENNSYLVANIA 19103-7599		
<b>ATTORNEY DOCKET NUMBER:</b>	079833		
<b>DOMESTIC REPRESENTATIVE</b>			
<b>Name:</b>	Paul Lantieri III		
<b>Address Line 1:</b>	1735 Market Street, 51st Floor		
<b>Address Line 4:</b>	Philadelphia, PENNSYLVANIA 19103-7599		

CH \$40.00 1742103

NAME OF SUBMITTER:	Paul Lantieri III
Signature:	/Paul Lantieri III/
Date:	01/31/2007
Total Attachments: 6 source=int49#page1.tif source=int49#page2.tif source=int49#page3.tif source=int49#page4.tif source=int49#page5.tif source=int49#page6.tif	

**ASSIGNMENT OF ALL RIGHTS IN CYTOMEGALOVIRUS IMMUNE GLOBULIN  
INTELLECTUAL PROPERTY**

WHEREAS, subject to the terms and conditions of the Asset Purchase Agreement, dated November 8, 2006 (the "**Agreement**"), by and among MedImmune, Inc., a Delaware corporation, having its principal offices at One MedImmune Way, Gaithersburg, Maryland 20878 ("**Assignor**") and ZLB Behring AG, a Swiss corporation having offices at Wankdorfstrasse 10, CH-3000 Bern 22, Switzerland ("**Assignee**"), Assignor has agreed to transfer to Assignee all of Assignor's rights in an invention known as "cytomegalovirus immune globulin" (the "**Product**"), including without limitation certain related trademarks, logos, domain names, copyrights, patents, patent applications, trade secrets and know-how (collectively, the "**CIG Intellectual Property**"); and

WHEREAS, Assignee has agreed to acquire the CIG Intellectual Property.

NOW, THEREFORE, intending to be legally bound, and for good and valuable consideration, receipt and sufficiency of which are hereby acknowledged, Assignor and Assignee agree as follows:

1. Assignor hereby sells, assigns, and transfers to Assignee all of Assignor's right, title, and interest in and to, including without limitation the right to sue for any and all past or future infringement or other misuse of, the CIG Intellectual Property, together with all renewals and extensions of such CIG Intellectual Property that may be obtained under the laws now or hereafter in force and effect in the United States of America and any other country or countries, more specifically but without limitation:

a. The trademark CytoGam, including without limitation all goodwill symbolized thereby and all registrations and any pending applications for registration or renewal thereof, in the United States Patent and Trademark Office, the Canadian Intellectual Property Office, the Deutsche Patent- und Markenamt (German Patent and Trademark Office), and the Turkish Patent Institute (the "**Trademark**"):

<u>TRADEMARK</u>	<u>GOODS</u>		
CytoGam	Cytomegalovirus immune globulin		
<u>Country</u>	<u>Registration No.</u>	<u>Registration Date</u>	
Canada	467424	12/10/1996	
Germany	2100031	04/22/1996	
Turkey	153481	06/01/1994	
U.S.	1,742,103	12/22/1992;	

b. Those certain unregistered graphic patterns, copies of which are attached hereto as Exhibit A (the "**Logo**"), which were used by Assignor in association with the Trademark in the United States, Canada, Germany and Turkey and which are being transferred to Assignee

worldwide, without limitation as to territory, together with all goodwill symbolized thereby;

c. That certain domain name (the "**Domain Name**") which is listed on Exhibit B attached hereto;

d. All copyrights (the "**Copyrights**") in works solely and exclusively related to the Product-Related Business (as defined in the Agreement); and

e. As owned by Assignor and exclusively related to the Product: the research and development information, validation methods and procedures, unpatented inventions, know-how, trade secrets, technical or other data or information, or other materials, methods, procedures, processes, materials, developments or technology, including all biological, chemical, clinical, manufacturing, marketing, sales and/or other information or data developed by Assignor, in any and all forms whatsoever (collectively, the "**Product Trade Secrets and Know-How**").

2. Assignor hereby authorizes the relevant trademark offices, domain name registrars, copyright offices, and other governmental or regulatory authorities to issue all future registrations and other rights to Assignee.

3. Assignor shall execute any additional documents reasonably requested by Assignee at any time in the future to enable it to protect, perfect, enforce, or otherwise secure Assignee's rights in and/or ownership of the Trademark, the Logo, the Domain Name, the Copyrights and the Product Trade Secrets and Know-How.

4. In the event of any conflict or inconsistency between the terms, provisions and conditions of this Assignment and the Agreement, the terms, provisions and conditions of the Agreement shall govern.


*[Signature on following page]*



**Exhibit A**  
**CytoGam Logos**

See Attached.

Logos



**Exhibit B**

**Domain Name**

**CYTOGAM.com**